Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
Holding EVAX?
Track your performance easily
Earnings Data
Report Date
Apr 08, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.42Last Year’s EPS
$0.03Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: -67.75%
|Next Earnings Date:Apr 08, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including a transformative agreement with MSD and solid pipeline progress, but also noted challenges with NASDAQ compliance and business development income targets.Company Guidance
During the Evaxion Q3 2024 earnings call, key guidance was provided, highlighting significant achievements and financial metrics. The transformative deal with MSD, signed in September, was emphasized, with an upfront payment of $3.2 million received in October and potential milestone payments of up to $592 million per product, plus royalties. Revenue for Q3 was $3 million, primarily from the MSD agreement, and the company reported a net loss of $1.9 million, an improvement from the $5.7 million loss in the same quarter last year. Cash and cash equivalents stood at $4.6 million as of September 30, 2024, with the expectation to fund operations until March 2025. The company also discussed its NASDAQ deficiency letter and plans to achieve compliance, aiming for an additional 180-day extension. Evaxion's strategy execution remains strong, with continued progress in R&D and business development, anticipating additional business development income in 2025.Transformative MSD Agreement
Evaxion signed a significant deal with MSD for EVX-B2 and B3, providing strategic and financial value. Received a $3.2 million upfront payment with potential milestone payments of up to $592 million per product plus royalties on sales.
Solid Pipeline Progress
Released 1-year clinical data from the Phase II trial with EVX-01, showing a 69% overall response rate. Presented proof of concept for mRNA-based B2 vaccine and launched an upgraded version of the EDEN model.
Financial Highlights
Recorded revenue of $3 million for Q3 2024. Executed cost reduction initiatives with lower G&A spending compared to the same period in 2023. Cash and cash equivalents were $4.6 million as of the end of September.
---
EVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $2.76 | $2.67 | -3.26% |
| Aug 14, 2024 | $2.70 | $2.75 | +1.85% |
| May 28, 2024 | $4.04 | $3.83 | -5.20% |
| Mar 27, 2024 | $3.13 | $3.00 | -4.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evaxion Biotech (EVAX) report earnings?
Evaxion Biotech (EVAX) is schdueled to report earning on Apr 08, 2025, TBA Not Confirmed.
What is Evaxion Biotech (EVAX) earnings time?
Evaxion Biotech (EVAX) earnings time is at Apr 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVAX EPS forecast?
EVAX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.42.
---